R&D channel feed – Endpoints News

R&D channel feed

Halia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trial

5 months ago

Early data suggest Arvinas, Pfizer could combine their breast cancer drug with Lilly’s Verzenio

5 months ago

BioNTech reports early survival data for VEGF bispecific, weeks after buying Chinese partner

5 months ago

Olema Oncology makes case for its oral SERD with fresh data cut from early breast cancer trial

5 months ago

BTK inhibitors from AstraZeneca, Eli Lilly and BeiGene take center stage in CLL

5 months ago

Arcellx and Gilead seek to unseat Legend and J&J with multiple myeloma cell therapy

5 months ago

Kura Oncology details 'aggressive' approach in first-line AML

5 months ago

Retrospective analysis shows potential for GLP-1s to treat blood clots

5 months ago

GSK reports Blenrep overall survival data in multiple myeloma as it plots market reentry

5 months ago

ICER finds Vertex's non-opioid pain treatment could bring cost savings at a lower price

5 months ago

AbbVie, Genmab tout Epkinly combos in earlier lines of non-Hodgkin lymphoma

5 months ago

AbbVie declares third Phase 3 Parkinson’s win from Cerevel takeover

5 months ago

Merck's Keytruda combo misses overall survival in Phase 3 trial in ovarian cancer

5 months ago

Beam shares results from seven patients who received gene-edited sickle cell therapy

5 months ago

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

5 months ago

BioAge Labs scraps Phase 2 obesity trial just months after IPO

5 months ago

Novartis bolsters Fabhalta data in competition with AstraZeneca

5 months ago

After switching regulatory plans, AstraZeneca and Daiichi report pooled ADC data in mutant lung cancer

5 months ago

BioNTech, DualityBio offer first glimpse at partnered ADC in solid tumors

5 months ago

Biosecure compromise could add executive review process for named companies, sources say

5 months ago

Protara’s stock nearly doubles as biotech divulges new bladder cancer data

5 months ago

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

5 months ago

CG Oncology’s bladder cancer treatment shows durability potential in Phase 3

5 months ago

Moderna CEO defends pandemic prep efforts with critics set to enter Trump’s administration

5 months ago

First page Previous page 13 14 151617 18 19 Next page Last page